Showing posts with label Launches. Show all posts
Showing posts with label Launches. Show all posts

Tuesday, April 5, 2011

SLaM Launches New Intensive Programme For Adolescent Anorexia, UK

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8973.

Main Category: Eating Disorders
Article Date: 01 Feb 2011 - 0:00 PST window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
2 starsnot yet rated
South London and Maudsley NHS Foundation Trust (SLaM) has just launched an innovative new intensive treatment program for adolescents suffering from anorexia nervosa.

The new day programme combines a range of group and family-based therapies, as well as time for the young person to continue their education with the support of a teacher and teaching assistant. Staff and young people will eat together, to provide support at meal times.

A specialist national service, it is open to young people diagnosed with anorexia aged between 11 and 18 years, and from anywhere across the United Kingdom.

Jo Fletcher, Deputy Director of CAMHS National and Specialist Service, said the intensive programme would treat more serious cases of anorexia and use family based treatment to overcome the need for hospitalisation.

"As a team, we are confident that committed participation in the programme offers young people and their families' real hope of overcoming their illness and beginning recovery."

The programme is designed to be therapeutic, fun and creative, and includes a range of activities. Activities and groups on offer include cognitive behaviour therapy, mindfulness and managing your relationships, groups about nutrition, relaxation and the effects of anorexia on mind and body.

Each young person and their family will be allocated a key worker who will be their main point of contact for the duration of their time in the programme. Their ongoing care coordinator will also be involved in the treatment.

The day programme will follow a similar pattern to school, with patients attending from 8:00 am to 8:00 pm Monday to Thursday, with a shorter day on Friday. After attending the programme for a period of six weeks, patients will then begin multi-family therapy.

Unlike inpatient care, the programme allows young people to spend evenings and weekends with their families in order to put into practice the skills they have learnt during the week. Families are encouraged to give feedback after the weekend and strong family involvement is fundamental to the success of the programme.

Ms Fletcher said most treatments for children and adolescents suffering anorexia involve long hospital stays, averaging between six months and a year.

"Unfortunately, dedicated specialist services for young people with anorexia are limited across the United Kingdom. At the Maudsley, we are at the forefront of developing family-based treatments for children and young people with anorexia nervosa."

The National Institute for Clinical Excellence (NICE, 2004) recommends that whenever possible adolescent patients should be treated for anorexia on an outpatient basis by a service that has expertise both in the psychological aspects of the treatment and in assessing the physical risk associated with eating disorders.

NICE also emphasises the importance of family interventions, and age-appropriate facilities for children and adolescents including educational activities.

Ms Fletcher said SLaM's child and adolescent Eating Disorders Service has been developed through many years of research and clinical experience.

"SLaM's research is internationally recognised. The 'Maudsley Family Therapy', also known as 'Family-Based Treatment' or the 'Maudsley Approach', was pioneered at at SLaM in the mid 1980's to treat anorexia nervosa in adolescents. It is now used across the world to treat a wide-range of mental health conditions."

The Maudsley Approach is an intensive outpatient treatment method where parents play an active and positive role. Instead of blaming the family situation for contributing to the development of eating disorders, it uses parents as an essential resource in treating anorexia.

Today, 90 to 95 per cent of children and adolescents treated for eating disorders at SLaM are treated on an outpatient basis. Young people requiring hospitalisation for eating disorders at SLaM is around 20 per cent of the national average.

"The new day care programme is aimed specifically at those remaining 20 per cent of chronically ill patients who are likely to end up in hospital. Through this new intensive approach, we hope to work closely with their family to put them on a path to recovery and keep them out of hospital."

The day care programme is located with in the current at SLaM's Michael Rutter Centre for Children and Young people, and compliments SLaM's other outpatient and inpatient national specialist eating disorder services for children and adults.

Feedback from former patients and family

"Bringing out daughter to the Eating Disorders Service helped to turn things around by empowering us and involving us as collaborative partners in her regaining her health in a way that we had not been made to feel with our previous local service. We are very pleased with the help we received!" Parent of a former patient

"Taking part in the multi-family group treatment helped me to realise just how anorexia had robbed me of the life I wanted; in that sense I got better quickly. With whole days in a row of non-stop anorexia bashing talk, I couldn't continue to bury my head in the sand, could I?" Former patient, age 16

A typical day in the Intensive Treatment Programme:

All young people participating in the programme will attend from 8am to 8pm and participate in all groups. All meals and snacks will be provided, and the young people will eat alongside staff members.

8:15 - 9:00 Breakfast
9:00 - 10:00 Education
10:00 - 11:00 CBT for worries
11:00 - 11:30 Snack break
11:30 - 12:15 Physical checks
12:15 - 13:00 Mindfulness
13:00 - 14:00 Lunch
14:00 - 15:00 Education
15:00 - 15:45 Managing emotions
15:45 - 16:15 Snack break
16:15 - 17:00 Art group
17:00 - 18:00 Physical healthcare group
18:00 - 18:45 Dinner
18:45 - 20:00 Family time

Notes

- For more information on SLaM's CAMHS Eating Disorder Services visit here.

- SLaM's eating disorder treatment is provided mainly on an outpatient basis and includes the Multi-family Therapy (MFT) programme, for which we received the Positive Practice Award from the National Institute for Mental Health in England, in 2004.

- SLaM's CAMHS services are renowned both in the UK and internationally, with clinical practice that thrives on links with the Institute of Psychiatry (IoP) and the Medical Research Council Child Psychiatry Unit.

- SLaM's Eating Disorder Service for children and adolescents is located within the Michael Rutter Centre for Children and Young People at the Maudsley Hospital, Denmark Hill, London SE5 8AZ.

Source:
SLaM

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Saturday, March 26, 2011

ASP Launches The Fastest Low-Temperature Sterilization Cycle On The Market


Main Category: Medical Devices / Diagnostics
Article Date: 21 Mar 2011 - 3:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions
not yet ratednot yet rated
Advanced Sterilization Products (ASP) announced the availability of the EXPRESS Cycle for the STERRAD® 100NX™ System. This is the fastest low-temperature sterilization cycle validated for surface sterilization of da Vinci® 3D endoscopes, rigid telescopes, rechargeable batteries and many other devices. The EXPRESS Cycle rapidly sterilizes instruments without the damage associated with other sterilization modalities.

The EXPRESS Cycle is a feature upgrade that customers can purchase for their new or existing STERRAD® 100NX™ Systems. The 24-minute EXPRESS Cycle joins the 42-minute FLEX and 47-minute STANDARD cycles on the STERRAD® 100NX™ System platform, creating an unrivaled range of sterilization options.

"The addition of the EXPRESS Cycle continues our focus on optimizing our customers' investment in the STERRAD® 100NX™ System," said Karen Borg, Vice President of Worldwide Marketing for ASP. "Our breadth of cycles combined with first-class technical support and clinical education, ensures our customers have the most flexible and long-term sterilization solution."

The STERRAD® 100NX™ System EXPRESS Cycle is now available in the U.S., Europe, Middle East and Africa (EMEA).

About STERRAD® Sterilization Systems

With thousands of units in use at hospitals and healthcare facilities around the world, STERRAD® Sterilization Systems offers a broad range of solutions for low-temperature sterilization. Engineered using the breakthrough hydrogen peroxide gas plasma technology of ASP, STERRAD® Sterilization Systems sterilize medical devices safely and effectively, without the limitations or risks associated with peracetic acid, steam and ethylene oxide gas systems. STERRAD® Sterilization Systems produce a measurable return on a hospital's investment by reducing instrument repair costs, offering rapid cycles, reducing instrument inventories and enhancing safety.

Source:
Advanced Sterilization Products (ASP)

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here

Friday, March 25, 2011

RainDance Technologies Launches Two Comprehensive Genetic Screening Research Tools For Identifying Mutations Associated With X-Chromosome And ASD

Error in deserializing body of reply message for operation 'Translate'. The maximum string content length quota (8192) has been exceeded while reading XML data. This quota may be increased by changing the MaxStringContentLength property on the XmlDictionaryReaderQuotas object used when creating the XML reader. Line 1, position 8893.

Main Category: Autism
Also Included In: Genetics
Article Date: 21 Mar 2011 - 4:00 PDT window.fbAsyncInit = function() { FB.init({ appId: 'aa16a4bf93f23f07eb33109d5f1134d3', status: true, cookie: true, xfbml: true, channelUrl: 'http://www.medicalnewstoday.com/scripts/facebooklike.html'}); }; (function() { var e = document.createElement('script'); e.async = true; e.src = document.location.protocol + '//connect.facebook.net/en_US/all.js'; document.getElementById('fb-root').appendChild(e); }()); email icon email to a friend   printer icon printer friendly   write icon opinions  
not yet ratednot yet rated
RainDance Technologies, Inc., today announced the commercial availability of the ASDSeq™ and XSeq™ Research Screening Panels. Developed in collaboration with Emory University and Greenwood Genetic Center, the two comprehensive panels enable researchers to simultaneously interrogate key genes known to be linked to X-chromosome disorders and syndromic forms of Autism Spectrum Disorder (ASD) using next-generation sequencing. The announcement was made at the 20th Annual Clinical Genetics Meeting (ACMG) in Vancouver, British Columbia, Canada.

"The RainDance panels enable us to apply next-generation sequencing more routinely to projects focused on the specific genetic mutations that contribute to autism and other X-linked disorders."

Recent scientific findings indicate there are more than 800 protein-coding genes on the X chromosome, including many that play a role in autism and other developmental disorders1,2. To date, the widespread investigation of these genes has been constrained by the high experimental cost of current methods and inadequate analytic resolution. Commonly used technologies, such as microarrays and real-time PCR, have made it difficult to detect many of the important sequence mutations associated with these complex disorders. The RainDance ASDSeq™ panel and XSeq™ panel are based on the company's proven microdroplet-based targeted sequencing technology, which features the industry's leading coverage for detecting mutations central to understanding these types of disorders.

"Whole-genome and whole-exome sequencing methods are still too expensive; the large amount of data is difficult to manage in a clinical laboratory; and hybridization-based capture methods lack the required genomic coverage and specificity to target many of these important genes," said Madhuri Hegde, Ph.D., FACMG, Senior Director of Emory Genetics Laboratory and Associate Professor in the Department of Human Genetics, Emory University School of Medicine. "The RainDance panels enable us to apply next-generation sequencing more routinely to projects focused on the specific genetic mutations that contribute to autism and other X-linked disorders."

ASDSeq™ Panel

The RainDance ASDSeq Research Screening Panel uses next-generation DNA sequencing to offer more than 92 percent design coverage across 62 genes that contain mutations known to be associated with ASD. Covered gene targets include all exons for each gene, 1 kilobase of the 5-prime promoter region and 3-prime untranslated regions (UTRs), as well as 50 bases upstream and downstream of each exon to capture intron/exon splice junctions. The genes represented in the ASDSeq panel include autosomal (BRAF, FMR1, FOLR1, PNKP, PTPN11, SLC2A1, TCF4 and ZEB2) as well as X-linked (HPRT and NHS) forms of the disorders.

"With an estimated 1.5 million Americans living with the effects of autism, getting to the genetic underpinnings of this complex condition is one of the critical healthcare research challenges of our time," said Michael Friez, Ph.D., Director of Diagnostic Laboratories at the Greenwood Genetic Center. "As an organization dedicated to the practical application of medical advances to the care and treatment of families impacted by genetic disease and birth defects, we are encouraged by the potential contribution these innovative panels will have on the growing number of critical research projects being conducted around the world."

XSeq™ Panel

The RainDance XSeq Research Screening Panel also utilizes next-generation DNA sequencing to offer more than 98 percent coverage of the more than 1,000 genes encoded on the gene-rich human X chromosome3. This includes more than 600 genes that have yet to be associated with a Mendelian disease and all known Mendelian disorder genes. Coverage includes all exons, the 5-prime promoter region and 3-prime UTR for each gene. A few of the commonly sequenced genes represented in the XSeq panel, which can be sequenced together in a single powerful assay method, include ALD, DMD, FMR1, GLA and IL2RG.

"For the first time, we have access to a cost-effective solution that allows us to use next-generation sequencing to simultaneously interrogate more than 1,000 genes on the X chromosome," said Michael Zwick, Ph.D., Assistant Professor, Emory University. "This allows us to generate accurate, consistent and reproducible data at a fraction of the overall sample cost compared to previous sequencing methods."

Roopom Banerjee, CEO of RainDance Technologies, added, "These two research panels are excellent examples of how RainDance is collaborating with leading scientific institutions to bring powerful genetic research solutions to projects that will expand our understanding of complex genetic disorders."

2011 ACMG Annual Clinical Genetics Meeting

RainDance will discuss the ASDSeq and XSeq Research Screening Panels during its Exhibitor Theater presentation at the ACMG meeting on March 18 at 11:35am PT in Theater 1. The company will also be demonstrating its microdroplet platform in its exhibition booth (#533). Emory Genetics Laboratory (#215) and Geenwood Genetic Center (#109) will also be exhibiting at the meeting.

References

1 . Ross et al. (2005). The DNA sequence of the human X chromosome. Nature. Mar 17;434(7031):325-37.

2 . Tarpey et al. (2009). A systematic, large-scale resequencing screen of X-chromosome coding exons in mental retardation. Nat Genet. May;41(5):535-43.

3. Ibid.

Source.
RainDance Technologies, Inc.

Bookmark and Share

Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.

Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.

If you write about specific medications or operations, please do not name health care professionals by name.

All opinions are moderated before being included (to stop spam)

Contact Our News Editors

For any corrections of factual information, or to contact the editors please use our feedback form.

Please send any medical news or health news press releases to:



MediLexicon International Ltd Logo
Privacy Policy | Terms and Conditions

MediLexicon International Ltd
Bexhill-on-Sea, UK
MediLexicon International Ltd © 2004-2011 All rights reserved.



View the original article here